Early heart test for amyloidosis in people with atrial fibrillation
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study uses special heart tests (AI-ECG and CT scan) to look for a hidden condition called cardiac amyloidosis, which can affect people with atrial fibrillation. Finding it early may help guide treatment and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have been diagnosed with atrial fibrillation (AF), either occasional or ongoing.
- You have at least one symptom or sign that could be a red flag for heart amyloidosis.
- You are able to have an ECG or CT scan as part of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses an artificial intelligence (AI) tool to read your heart's electrical activity (ECG) to help doctors better manage your atrial fibrillation (AFib), an irregular heartbeat that can increase stroke risk. By combining the ECG with a heart ultrasound (echocardiogram), the AI aims to improve treatment decisions and outcomes.
This trial uses an artificial intelligence tool to read your heart's electrical signals and check how well your heart is recovering after a procedure to fix an irregular heartbeat called atrial fibrillation. It aims to find early signs of heart failure and guide better care.
This study measures how well the heart’s tiny blood vessels work in people with cardiac amyloidosis, using special heart testing. It may help doctors understand the disease better and improve how patients are evaluated over time.
This study uses artificial intelligence to analyze heart tests (ECGs) to help diagnose and predict outcomes for people with heart disease. It may lead to better and faster detection of heart conditions.
This study uses a special heart ultrasound to look for signs of cardiac amyloidosis, a condition where abnormal proteins build up in the heart. It may help diagnose the condition earlier and guide treatment.
This trial tests an AI program that looks at your heart ultrasound (echocardiogram) to find possible signs of cardiac amyloidosis early. It helps doctors decide if more testing is needed.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.